Antibodies
7 January 2013
Vaccinex, Inc. Announces Initiation of a Phase 1 Clinical Trial of VX15/2503 Antibody in Multiple Sclerosis Patients4 January 2013
Biogen Idec Submits Application to FDA for First Long-Lasting Factor IX Therapy for Hemophilia B27 December 2012
Astellas and UCB announce approval of Cimzia® (certolizumab pegol) in Japan for the treatment of adult patients with rheumatoid arthritis21 December 2012
Synthetic Biologics and Intrexon Corporation Initiate Development of Monoclonal Antibodies for Whooping Cough (Pertussis)21 December 2012
OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-52M51 (Anti-Notch1)19 December 2012
Phase I Clinical Trial of IPH2102/BMS-986015 in Combination With Ipilimumab Announced17 December 2012
Genmab Unveils a New Antibody Technology Platform: HexaBody17 December 2012
Allakos Inc. Completes Series A Financing of $32 Million to Develop Antibody Therapeutics for Allergic and Inflammatory Diseases17 December 2012
First Patient Treated in the EffiKIR Trial15 December 2012
GSK receives FDA approval for raxibacumab anti-toxin for the treatment of inhalational anthrax14 December 2012
Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab13 December 2012
Immunomedics Provides Clinical Updates on Subcutaneous Injections of Veltuzumab in Autoimmune Disease and Cancer13 December 2012
Immunomedics Develops New Bispecific Antibodies That Exhibit Potent Anti-Lymphoma Activity13 December 2012
Merrimack Pharmaceuticals Initiates Phase 1 Clinical Study of MM-141 in Patients With Advanced Solid Tumors13 December 2012
XBiotech Announces Positive Phase II Clinical Trial Results for Lead Candidate MABp1 in Acne Vulgaris13 December 2012
Lilly Provides Update on Next Steps for Solanezumab13 December 2012
Kyowa Hakko Kirin Initiates Pivotal Phase 3 Trial of Mogamulizumab (KW-0761) in Patients with Cutaneous T-Cell Lymphoma in the United States11 December 2012
Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A at ASH Annual Meeting11 December 2012
New Data Highlighting Long-Term Efficacy and Safety Outcomes of PNH Patients Treated with Soliris Reported at ASH Annual Meeting11 December 2012
Seattle Genetics Reports Data from Phase I Trial of ADCETRIS (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual Meeting11 December 2012
ImmunoGen, Inc. Announces IMGN901 Clinical Data Presented at ASHNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports